Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: A double-blind randomized controlled trial

Journal of SAFOG

Volumn 3, Issue 1, 2011, Pages 21-24

  Shravage, Jyotsna ^a   Mekhala, D ^a   Bellad, M B ^a   Ganachari, M S ^a   Dhumale, H A ^a  

^a JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

Author keywords

Dysfunctional uterine bleeding; Medroxyprogesterone acetate (MPA); Ormeloxifene; Progesterone

Indexed keywords

CENTCHROMAN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIUM; FEMALE; HUMAN; INDIA; MENSTRUAL CYCLE; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SANITARY PAD; SCORING SYSTEM; TEACHING HOSPITAL; THICKNESS; TRANSVAGINAL ECHOGRAPHY;

EID: 83755161511     PISSN: 09748938     EISSN: 09751920     Source Type: Journal    
DOI: 10.5005/jp-journals-10006-1116     Document Type: Article

References (16)

1. Fraser IS, Jansen RPS, Lobo RA, Whitehead MI. Oestrogens and progestogens in clinical practice, Chapter 35 "Dysfunctional Uterine Bleeding". Church II Living Stone Publication 1998; 419-37.
2. Hatasaka H. The evaluation of abnormal uterine bleeding. Clinical obstetrics and gynecology 2005;48(2):382-97.
3. Lethaby A, Irvine GA, Cameron IT. Cyclical progestogens for heavy menstrual bleeding. Cochrane database of systematic reviews 2008 (Issue 1). Art No CD001016. DOI: 10.1002/14651858.cd001016. pub.
4. Biswas SC, Saha SK, Bag TS, Ghosh Roy SC, Roy AC, Kabiraj SP. Ormeloxifene: A selective estrogen receptor modulator for treatment of dysfunctional menorrhagia. J Obstet Gynecol Ind 2004;54(1):56-59.
5. ACOG practice bulletin selective oestrogen receptor modulators. Clinical management guidelines for obstetricians and gynecologists 2002;39(4):835-44.
6. Wendy Shelly, Michael W Draper, Venkatesh Krishnan, Mayme Wong, Robert B Foffe. Selective oestrogen receptor modulators: An update on recent clinical findings. Obstetrical and gynecological survey Mar 2008;63(3):163-81.
7. Speroff L, Fritz M. Clinical gynecologic endocrinology and infertility, Chapter 15 "Dysfunctional Uterine Bleeding" (7th ed). Lipcott Williams and Willkins 2005;547-73.
8. Shaw RW. Assessment of medical treatment for menorrhagia. Br J Obst and Gynecol Jul 1994;101 (Suppl 11):15-18.
9. Studd J. Progress in obstetrics and gynecology, Chapter 17 "Abnormal uterine bleeding: Diagnosis and medical management". Churchill living stone 2003;12:309-27.
10. Living Stone M, Eraser IS. Mechanism of abnormal uterine bleeding. Human reprod update 2002;8(1):60-67.
11. Lethoby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane database of systematic reviews 2007 (Issue 4). Art No CD00400: DOI: 10.1002/14651858 Pub 2.
12. Prasad S Centchroman. A novel drug for DUB J. Obstet Gynecol India 2000;50:77-79.
13. Davey DA. Dysfunctional uterine bleeding. In: Whitefield CR (Ed). Dewhursts textboon of obstetrics and gynecology for postgraduates (5th ed). London: Blackwell Scientific 1995;509.
14. Kriplami A, Kulshrestha V, Agarwal N. Efficacy and safety of ormeloxifene in the management of menorrhagia: A pilot study. The journal of obstetrics and gynecol research 2009;35(4): 746-52.
15. Higham JM, Obrien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. British journal of obstetrics and gynecology 1990;97:734-39.
16. Jassen AH, Scholten PC, Heint PM. A simple visual assessment technique to discriminate between monorrhagia and normal menstrual blood loss. Obstetrics and gynecology 1995; 85(6):977-82.